Bioengineering human liver organoids

A living substitute for a failing liver.

Kanzo Biomedicines engineers human liver organoids from iPS cells to treat patients with severe liver failure — starting with an extracorporeal system that keeps patients alive while their own liver recovers.

See how it works Get in touch

"Nearly fifteen years ago, I witnessed transplant medicine firsthand — and wanted to change a reality where liver transplantation was the only treatment available. That is why I began this research. With liver organoids grown from iPS cells, I want to give patients who could only wait a new option. Bringing UTOpiA to the clinic as soon as possible — that is my promise."

Takanori Takebe, MD PhD — Founder

The issue

Liver failure is a leading cause of death worldwide, and treatment options remain limited.

Liver transplantation is curative, but donor availability is limited and long wait lists drive high mortality. Existing extracorporeal and cell-based alternatives have shown minimal efficacy or raise safety concerns.

~2M

deaths caused by liver disease worldwide each year

20–80%

mortality rate for acute-on-chronic liver failure (ACLF)

$14B

estimated addressable market across the US, EU, and Japan

Sources: Devarbhavi et al., 2024 (mortality figures). Total addressable market: company analysis.

Our solution

Human liver organoids, engineered from iPS cells.

We have established a reproducible process for generating endodermal tissue from induced pluripotent stem cells, producing organoids that are transcriptomically and functionally close to native liver — not just isolated hepatocytes.

Highly functional organoids

Superior liver functionality — albumin production, detoxification, and biogenesis of key hepatic proteins — compared to conventional hepatocyte cell line-based systems (e.g., HepG2/C3A).

Scalable iPSC source

Because our organoids are derived from iPSCs, we have an effectively unlimited supply of starting material for manufacturing at scale. The cells are additionally engineered to be hypoimmune, reducing the immune response associated with allogeneic therapy.

Favorable safety profile

Designed to minimize complications from therapy, avoiding the inflammatory response associated with xenografts.

First product

UTOpiA — an extracorporeal liver support system

Universal Tandem Optimized induced Hepatocyte-Like-Cells with Apheresis. Blood is circulated through a granulocyte-removal column paired with a column of our liver organoids, temporarily taking over the liver's job while a patient's own liver recovers.

Temporarily substitutes impaired metabolic function of the liver
Suppresses the systemic inflammation associated with liver failure
Promotes regeneration of the patient's own liver

How it works

Patient blood ↓

GMA column ↓

iHLC column ↓

Returned to patient

HLO: human liver organoid, composed of induced hepatocyte-like cells (iHLC). GMA: granulocyte and monocyte adsorption apheresis.

Read the published study → Read the Osaka University research news →

Company

A cross-border team, built for both sides of the Pacific.

Kanzo Biomedicines operates as two coordinated entities, each drawing on the funding and collaborator ecosystem of its home market.

United States

Kanzo Biomedicines, Inc.

Management, financing, and commercialization
Late-stage clinical development
Non-dilutive funding via CIRM, SBIR, and NSF

Japan

Kanzo Biomedicines Japan K.K.

Core research and CMC development
Early clinical development
Non-dilutive funding via AMED, with CDMO and university collaborators